Warning: count(): Parameter must be an array or an object that implements Countable in /home/customer/www/drugtrialsformoney.com/public_html/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 373
Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer - Drug Trials For Money - Paid Clinical Trials

Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer

Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer
Conditions:   Metastatic Pancreatic Adenocarcinoma;   Recurrent Pancreatic Adenocarcinoma;   Stage II Pancreatic Cancer AJCC v8;   Stage IIA Pancreatic Cancer AJCC v8;   Stage IIB Pancreatic Cancer AJCC v8;   Stage III Pancreatic Cancer AJCC v8;   Stage IV Pancreatic Cancer AJCC v8;   Unresectable Pancreatic Carcinoma
Interventions:   Biological: Anetumab Ravtansine;   Drug: Gemcitabine Hydrochloride;   Biological: Ipilimumab;   Biological: Nivolumab
Sponsor:   National Cancer Institute (NCI)
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

June 30, 2022 / by / in
Comments